Glucose 30% Intravenous Solution: Measurement of IDVG on admission, at 4 hours (H+4), and at 8, 16, 24, 48, 72 and 96 hours (H+8, H+16, H+24, H+48, H+72 and H+96) post-burn. The principle of this measurement consists of taking a reference blood glucose level measured on an arterial blood sample (arterial catheter) using a blood glucose meter. A bolus of 5g of glucose is injected into a central venous line over 30 seconds. A second blood glucose level is measured 3 minutes after the end of the injection.
The intra-thoracic blood volume (ITBV) and extra-vascular lung water (EVLW) are measured using the PiCCO device as part of the usual management of burn patients.
Study summary
This is a prospective, observational, monocentric, phase II (exploratory) cohort study aiming to describe the evolutionary profile of the initial volume of glucose distribution (IDVG) during the first four days of management of severely burned patient.
Eligibility
Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria:
* Patients over 18 years of age
* Patients hospitalized with burns of at least 30% of body surface area
* By a thermal mechanism
* At the CHR Metz-Thionville burn center
* managed within the 8 hours post-burn
* Patient affiliated to a social security scheme
* Written consent obtained from the patient (or from the trusted person, family or relatives if the patient is unable to sign/express consent) or emergency inclusion if the patient is unable to express consent and neither the trusted support person nor any member of the family or relatives is present at the time of inclusion.
Exclusion Criteria:
* Diabetic patients on insulin
* Patient with a CONTRAINDICATION to GLUCOSE 30% PROAMP, solution for injection
* Patients with pre-hospital cardiac arrest
* extra corporeal circulation patient: Extra Corporeal Membranous Oxygenation (ECMO) or Extra Corporeal Life Support (ECLS) or CRRT (Continuous Renal Replacement Therapy)
* patient without a central venous line or arterial catheter
* Patient moribund or immediately subject to therapeutic limitation
* Impossibility of trans-pulmonary thermodilution monitoring (vascular access difficulties)
* Pregnant, parturient or breast-feeding women
* Patient under guardianship, curatorship or safeguard of justice
* Cognitive impairment or language barrier
Primary outcome measure(s)
Description of the mean values of the initial volume of glucose distribution (IDVG) — on admission, at Hours 4, 8, 16, 24, 48, 72 and 96 post-burn The IDVG is calculated according to the method described by Hitota et al. A reference blood glucose level is measured on an arterial blood sample (arterial catheter) by a blood glucose meter. A bolus of 5 g of glucose is injected into a central venous line over 30 seconds.
A second blood glucose level is measured 3 minutes after the end of the injection.
The difference between the two blood glucose levels is recorded as d\[glu\] in mg/dl.
IDVG = 24.4 x e(-0.0298 \* d\[glu\]) + 2.7 in liters
Trial sites (1)
Facility
City
Region
Status
CHR Metz-Thionville/Hopital de Mercy
Metz
France
Recruiting
More Centre Hospitalier Régional Metz-Thionville trials in France
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.
